Payment overview · 2025
General Payments
$278.83
13 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey R. Jamison, D.O
Allopathic & Osteopathic Physicians|Family Medicine · SPOKANE, WA · NPI 1811068836
Verified facts
What the public records show
CMS Open Payments records show Jeffrey R. Jamison, D.O received $278.83 in general payments during 2025 across 13 reported records.
Medtronic, Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$54.54 | 19.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.61 | 17.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.37 | 10.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.94 | 8.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.65 | 8.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.39 | 7.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.68 | 7.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.66 | 7.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.56 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.43 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.83 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $31.98 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 69 |
| Lisinopril | Lisinopril | 238 | 68 |
| Omeprazole | Omeprazole | 187 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 36 |
| Gabapentin | Gabapentin | 165 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 47 |
| Losartan Potassium | Losartan Potassium | 154 | 51 |
| Furosemide | Furosemide | 140 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 30 |
| Meloxicam | Meloxicam | 106 | 22 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Simvastatin | Simvastatin | 94 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 11 |
| Eliquis | Apixaban | 83 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 17 |
| Tramadol Hcl | Tramadol Hcl | 82 | 16 |
| Potassium Chloride | Potassium Chloride | 80 | 20 |
| Methocarbamol | Methocarbamol | 73 | 19 |
| Metformin Hcl Er | Metformin Hcl | 72 | 21 |
| Allopurinol | Allopurinol | 69 | 20 |
| Lorazepam | Lorazepam | 65 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Alendronate Sodium | Alendronate Sodium | 59 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 28 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 16 |
| Baclofen | Baclofen | 54 | suppressed |
| Methadone Hcl | Methadone Hcl | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 51 | 16 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | 16 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 15 |
| Alprazolam | Alprazolam | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 11 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 12 |
| Ozempic | Semaglutide | 39 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Azithromycin | Azithromycin | 34 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Prednisone | Prednisone | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 18 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Buprenorphine | Buprenorphine | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.83 · 13 records | Medtronic, Inc. | AUSTEDO XR, Dexcom G6 Transmitter, EVENITY, JARDIANCE, JOURNAVX, KYPHON EXPRESS II KYPHOPAK TRAY, LEQVIO, MINIMED 780G, NURTEC ODT, Ozempic, Rybelsus, VRAYLAR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error